Warfarin falters as Boehringer's Pradaxa positive in VTE treatment
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim's Pradaxa (dabigatran) was non-inferior to warfarin in treating patients who had suffered acute venous thromboembolism (VTE) in the RE-COVER study. The results – presented at an American Society of Hematology meeting in New Orleans and published simultaneously in the NEJM – provide support for extending the label of the drug, which is already approved in the EU for preventing VTE in orthopaedic surgery patients.